The use of autologous dendritic cell vaccine in the treatment of chondrosarcomas: a clinical case
Abstract
Soft tissue sarcomas belong to a rare group of highly malignant tumors that respond poorly to chemotherapy. A case of a 50-year-old male patient suffering from a tibial chondrosarcoma of the soft tissues is presented; the disease progression after first-line chemotherapy was revealed and treatment with autologous dendritic cell vaccine was initiated. During vaccine treatment for 19 months the patient’s condition is stable. his treatment continues.
About the Authors
U. I. Komarov
N.N. Petrov Research Institute of oncology
Russian Federation
Russian Federation
St-Petersburg
A. I. Semenova
N.N. Petrov Research Institute of oncology
Russian Federation
Russian Federation
St-Petersburg
I. A. Baldueva
N.N. Petrov Research Institute of oncology
Russian Federation
Russian Federation
St-Petersburg
T. L. Nekhaeva
N.N. Petrov Research Institute of oncology
Russian Federation
Russian Federation
St-Petersburg
A. V. Novik
N.N. Petrov Research Institute of oncology
Russian Federation
Russian Federation
St-Petersburg
D. H. Latipova
N.N. Petrov Research Institute of oncology
Russian Federation
Russian Federation
St-Petersburg
S. A. Procenko
N.N. Petrov Research Institute of oncology
Russian Federation
Russian Federation
St-Petersburg
References
1. Fletcher C., D.M., Bridge J.A., Hogendoorn P., Mertens F. WHO Classification of Tumours of Soft Tissue and Bone. 2013, v. 5, 4th Edition.
2. Jemal A., Siegel R., Ward E. et al. Cancer statistics, 2007. CA: A Cancer Journal for Clinicians. 2007, v. 57, No. 1, p. 43-66.
3. Bramwell V.H., Anderson D., Charette M.L. et al. Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft-tissue sarcoma: a meta-analysis and clinical practice guideline. Sarcoma. 2000, v. 4, p. 103-112.
4. Karavasilis V., Seddon B.M., Ashley S. et al. Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients. Cancer. 2008, v. 112, No. 7, p. 1585-1591.
5. Qiu M.Z., Xu F., Wang S.S. et al. Responses of 109 adult soft tissue sarcoma patients to chemotherapy. Chinese Journal of Cancer. 2007, v. 26, No. 12, p. 1344-1349.
6. Li E.X., Zhang Y.T., Shang J.T. et al. Effect of modified MAID regimen for patients with advanced soft tissue sarcoma. Chinese Journal of Cancer. 2006, v. 25, No. 8, p. 1048-1051.
7. Lee S.H., ChangM.H., Baek K.K. et al. High-dose ifosfamide as second- or third-line chemotherapy in refractory bone and soft tissue sarcoma patient. Oncology. 2011, v. 80, No. 3-4, p. 257-261.
8. Italiano A., Mir O., Cioffi A. et al. Advanced chondrosarcomas: role of chemotherapy and survival. Annals of Oncology. 2013, v. 24, No. 11, p. 2916-2922.
9. Нехаева Т.Л., Данилова А.Б., Балдуева И.А. Лабораторный мониторинг иммунологической эффективности вакцин на основе аутологичных дендритных клеток (ДК) у больных меланомой кожи. Российский иммунологический журнал. 2013, т. 7 (16), № 2-3, с. 345.
10. Otavia L.C., Chen Y.T. Cancer/testis (CT) antigens: Potential targets for immunotherapy. Cancer Science. 2009, v. 100, No. 11, p. 2014-2021.
11. Stevenson B.J., Iseli C., Panji S. et al. Rapid evolution of cancer/testis genes on the X chromosome. BMC Genomics. 2007, v. 8, p. 129-139.
Review
For citations:
Komarov U.I., Semenova A.I., Baldueva I.A., Nekhaeva T.L., Novik A.V., Latipova D.H., Procenko S.A. The use of autologous dendritic cell vaccine in the treatment of chondrosarcomas: a clinical case. Bone and soft tissue sarcomas, tumors of the skin. 2014;(2):51-52. (In Russ.)
Views:
178
Email this article 
